疏肝健脾法对溃疡性结肠炎结肠黏膜中PPAR-γ相关因子基因和蛋白表达影响的研究
|
摘要
研究目的与意义
溃疡性结肠炎(uleerativeeolitis, UC)是一种病因不明的,主要累及直肠和乙状结肠的黏膜和黏膜下层的浅表性、非特异性炎症病变为主的消化道疾病,可扩展至降结肠、横结肠,少数可累及全结肠。其治疗难度非常大,且反复发作,缠绵难愈,被公认为是结肠癌的癌前病变,已经被世界卫生组织(WHO)列为现代社会最难治疗的疾病之一。现代医学对UC缺乏特效治疗药物,患者常因为并发症、手术、激素耐药或依赖问题而痛苦异常、造成患者严重的经济、家庭负担。UC在国外十分常见,我国UC发病率和患病率也非常高,且呈现逐年增加的态势。由于UC的病因和发病机制十分复杂,因而临床缺乏特异性治疗药物,部分患者因缺乏有效治疗而伴随终身,患者的生活质量已经受到严重影响。目前,针对UC的治疗药物主要有肾上腺皮质激素、水杨酸类、免疫抑制剂等,这些药物因为具有副反应多、停药后易复发,部分顽固性病例疗效不理想等缺点,限制了其在临床的使用。
中医药治疗UC具有副反应少、价格低廉、疗效显著、无依赖性、多靶点整体调节、复发率低、治病求本以及远期疗效稳定等优势,具有较好的深入研究与应用开发价值,受到消化内科专家的青睐。中医药防治UC的机理研究亦是近年来研究者追踪的前沿热点。目前,在中医药防治UC的实验研究方面,医家多偏重从“湿热”病机入手,以“清化湿热”立法,对治疗泄泻的经典方,如“白头翁汤”、“芍药汤”、“参苓白术散”等进行了深入研究,取得了诸多成果。但缺乏对UC“肝郁脾虚”病机及“疏肝健脾法”的探讨。根据临床所见及证候分布和治法研究,发现“肝郁脾虚证”是UC的重要证候,“疏肝健脾法”亦是治疗UC的重要方法,尤其是精神情绪因素“肝郁”既可能是UC发病的始动因素,亦可能是UC病情加重或缠绵难愈的重要原因。治则治法是连接病机和方药疗效的核心环节,从“肝郁脾虚”病机视角研究“疏肝健脾法”治疗UC的疗效机制和作用靶点,不仅可以拓展中医药治疗UC的思路,揭示中医治法的科学内涵,亦可为开发防治UC的特效中成药提供理论和实验依据,所以本研究具有较好的应用前景和科学意义、现实意义。痛泻要方出自《丹溪心法》,由炒白术、炒白芍、防风、陈皮四味药组成,功能疏肝健脾,是治疗肝郁脾虚所致腹泻的经典方。回顾并研究古今近10年文献,发现临床运用痛泻要方或者痛泻要方的加减方治疗UC取得良好疗效的报道甚多,有较好的临床基础,但从实验角度研究其治疗UC的作用机理却鲜有报道。基于“肝郁脾虚证”是UC的重要证型,“肝郁脾虚”是UC的重要病机,“疏肝健脾法”是治疗UC的重要治法的认识,结合国内外鲜有研究“疏肝健脾法”治疗UC的作用机制,本研究以“疏肝健脾法”为指导,选用“疏肝健脾法”的代表方痛泻要方,针对UC“肝郁脾虚”基本病机,运用分子生物学实验技术,从基因和蛋白表达水平揭示痛泻要方治疗UC的分子机制,为其临床广泛运用提供实验依据。
研究方法：
本论文研究分为理论研究、实验研究两个部分。理论研究部分是在系统整理中医学对UC认识古今相关文献的基础上,结合现代医学对UC的研究进展,重点探讨了UC的中医病因病机,UC的免疫学发病机制,溃疡性结肠炎的证候分型、治法的分布规律,疏肝健脾法治疗UC的现状及本论文研究的主要思路。实验研究部分首先采用TNBS/乙醇灌肠法复建UC大鼠模型,在造模的不同时间段采用RT-PCR及ELISA法、免疫组化技术动态观察大鼠结肠组织NF-κB p65、PAR-γ、ICAM-1及血清TNF-α、IL-1β的动态表达、探讨了其在UC发病中的作用。其次是研究采用TNBS/乙醇灌肠+束缚法+饮食失节的复合方法建立大鼠肝郁脾虚型UC模型,并给予痛泻要方干预治疗,采用RT-PCR、免疫印迹及ELISA法检测其对UC大鼠结肠组织中PPARγ、NF-κB p65、ICAM-1表达以及血清中IL-1β、TNF-α水平的影响,一方面为治疗UC寻找新的作用靶点,另外一方面是从分子水平进一步探讨疏肝健脾法治疗UC作用机理。
研究结论及意义
1. TNBS/乙醇灌肠法可成功建立UC大鼠模型,肉眼观察及光镜镜观察均出现明显的炎症、溃疡。且结肠损伤随着造模时间不同呈现动态变化趋势,其中以3d和7d的病变最为严重,14d和21d天则炎症和溃疡有所修复。
2.在UC模型的急性期,结肠组织中PPAR-γ表达显著降低,慢性期PPAR-γ表达略有升高,但仍明显低于空白组。UC模型的急性期NF-κB p65、ICAM-1表达显著升高,慢性期,NF-κB p65、ICAM-1表达略有降低,但仍明显高于空白组。
3.促炎因子TNF-α、IL-1β和抗炎因子IL-4的平衡参与了UC的发生、发展。
4. PPAR-γ的表达与结肠组织损伤程度、IL-1β、TNF-α、NF-κB p65、ICAM-1的表达之间呈不同程度的负相关。
5.UC的发生与发展与PPAR-γ的表达受抑密切相关,上调PPAR-γ的表达有望成为UC治疗新靶向。
6.肝郁脾虚是UC的重要病机,肝郁脾虚证是UC的重要证候类型,疏肝健脾法是治疗UC的重要治法。
7.痛泻要方对肝郁脾虚型UC模型大鼠结肠组织具有良好的保护和修复作用,其分子机制可能是上调PPAR-y mRNA及蛋白表达,抑制结肠组织ICAM-1、 NF-κB p65mRNA及蛋白表达、抑制血清IL-1β、TNF-α的表达,从而减轻结肠炎症反应,起到治疗UC的作用。痛泻要方可能具有PPAR-γ激动剂的效用。
Purpose and Significance
Ulcerative colitis (uleerativeeolitis, UC) is a kind of unknown etiology, mainly involving the rectum and sigmoid colon mucosa and submucosa of the superficial, nonspecific inflammatory disease of digestive tract disease, can be extended to the descending colon, the transverse colon, minority can affects the colon, is difficult to cure, often recurrent, is considered to be precancerous lesions of the colon cancer, World Health Organization has been listed it as one of the modern difficult to treat. Modern medicine to UC is lack of a specific treatment, patients often bearing complications, surgery, hormone resistant or dependent abnormal pain, causing severe economic and family burden. Ulcerative colitis is quite common in Western countries, According to the ulcerative colitis-related documents and statistics the number of hospital cases show that its incidence is increasing year by year. Due to the complexity of the pathogenesis of UC, the cause is not yet very clear, due to the lack of effective treatment and specific clinical drug, for some patients accompanied by lifelong with abnormal pain, have serious impact on people's quality of life. At present, Drugs for UC are often salicylic acid, adrenal corticosteroids, immunosuppressants, etc. Most of them are easy to relapse after treatment, long-term medication side effects, for some stubborn cases, the effect is not ideal shortcomings.
In recent years, Chinese medicine in the treatment of UC achieved more satisfactory results, and has little side effects, low recurrence rate and long-term efficacy advantage with better research and development value, favored by the Department of Gastroenterology experts, it is the tracked hotspots in recent years that the Mechanism research on Traditional Chinese Medicine to UC. At present, mechanism on Traditional Chinese Medicine to treatment UC, physicians more emphasis to start from the "Shire" pathogenesis and treatment of diarrhea classic recipe of the "Qinghuashire", such as "Pulsatilla soup","Peony soup","Shenlingbaishu powder" made a lot of achievements. But, according to clinical diagnosis, stagnation and spleen deficiency is important pathogenesis of UC,"Shuganjianpi" is an important method for the treatment of UC, especially the mental factor "liver depression" is probably UC incidence initiating factor, or hard to be cured reasons. The therapeutic principle is the core aspects of connected to the pathogenesis and recipe efficacy, clarify its efficacy mechanism and target of the treatment of UC's efficacy, from perspective of stagnation and spleen deficiency to study curative effect mechanism of "Shuganjianpi" treatment of UC, can not only expand the idea of Chinese medicine treatment of UC, revealing the scientific connotation of TCM treatments, also provide theoretical support for the development of prevention and treatment of UC proprietary Chinese medicines, all in all, this study has good application prospects and scientific significance and practical significance. Tong Xie Yao Fang from the "Danxi Experiences", composed of four herbs of fried Baizhu, fried Baishao, Fangfeng and Chenpi, its function is Shuganjianpi, it is the classic recipe for diarrhea raised by liver depression and spleen. Reviewed and studied nearly10years ancient and modern literature, it is found that the clinical use Tongxieyaofang or it's extend recipe for treatment of UC achieved good effect, with good clinical basis, but it is rarely reported of treatment UC mechanism from the experimental perspective. Liver depression and spleen deficiency syndrome is important UC pattern of syndrome, stagnation and spleen deficiency is an important pathogenesis of UC,"Shuganjianpi" is the important treatment of UC, combined with domestic and international fresh research on "Shuganjianpi "treatment mechanism of UC, this study as guide of the "Shuganjianpi" treatment, choice its representative recipe of Tongxieyaofang, aim at basic pathogenesis of UC stagnation and spleen deficiency, focusing on the use of the experimental techniques of molecular biology, from geneand the level of protein expression reveal the TongxieYaofang treatment of the molecular mechanisms of UC, provided experiment basis for the clinical extensive application.
Research Methods
This thesis is divided into two parts, theoretical and experimental studies. The theoretical part finishing medical UC understanding of the basis of the ancient and modern literature, combined with the progress of modern medicine on UC's research, focuses on TCM etiology and pathogenesis of UC, immunology for UC, UC syndrome type, conquer the logistic regression, the main idea of the treatment of the UC status quo and the thesis Shuganjianpi treatment. First, study part apply the TNBS/ethanol enema rehabilitation UC rat model of experimental, in the modeling of different time periods by RT-PCR, Western blot and ELISA, immunohistochemistry technology dynamic observation of rat colon tissue of PPAR-γ, NF-κB p65, ICAM-1and serum IL-1β, TNF-α, dynamic expression, and to explore its role in the pathogenesis of UC. Followed by research to establish the rat liver depression and spleen UC model TNBS/ethanol+binding method+diet disloyal composite method and treatment to give TongxueYaofang intervention, observation of UC colon tissue of PPARγ and NF-κB p65, ICAM-1content and the level of serum IL-1β, TNF-α, on the one hand, looking for a new role in the treatment of UC target, other hand, from the genetic level to further explore the mechanism of action of the Shuganjianpi treatment of UC, to provide a theoretical basis for its clinical application and development of new compound Chinese medicine.
Conclusions and Significance
a. TNBS/ethanol enema can be successfully established rat model of UC, observation from naked eye and microscopic, all showed inflammation and ulcers, and colon injury are dynamic modeling time trend, which is most severe lesions3d and7d,14d and21d days, some repair of the inflammation and ulceration would be appear.
b. In the acute phase of the UC model, PPARγ expression in colonic tissue was significantly reduced, the chronic phase PPARγ expression slightly elevated, but still lower than the blank group. UC model of the acute phase of NF-κB p65and ICAM-1expression was significantly increased in the chronic phase of NF-κB p65, ICAM-1expression slightly reduced, but still significantly higher than the blank group.
c. Proinflammatory cytokines TNF-α, IL-1β and anti-inflammatory cytokines IL-4balance involved in the occurrence of UC development.
d. PPAR-γ expression and colon tissue injury, IL-1β, TNF-α, NF-κB of p65, ICAM-1expression was negative correlation of different.
e. The occurrence and development of UC inhibited the expression of PPARγ is closely related to raised expression of PPAR-γ is expected to become the new targeted treatment of UC.
f. Liver stagnation and spleen deficiency is an important pathogenesis of ulcerative colitis; stagnation and spleen deficiency is important pathogenesis of UC,"Shuganjianpi" is an important method for the treatment of UC
g. Tong Xie Yao Fang has protection and repair function for the model of stagnation and spleen deficiency UC colon tissue, the molecular mechanism is up regulated PPAR-y mRNA and protein expression, inhibition of the colonic tissues ICAM-1, NF-κB p65mRNA and protein expression, suppression of serum IL-1β and TNF-α expression, so as to reduce the inflammatory reaction, and play a role in the treatment of UC. The TongXieYaofang may have PPAR agonist's utility.
溃疡性结肠炎(uleerativeeolitis, UC)是一种病因不明的,主要累及直肠和乙状结肠的黏膜和黏膜下层的浅表性、非特异性炎症病变为主的消化道疾病,可扩展至降结肠、横结肠,少数可累及全结肠。其治疗难度非常大,且反复发作,缠绵难愈,被公认为是结肠癌的癌前病变,已经被世界卫生组织(WHO)列为现代社会最难治疗的疾病之一。现代医学对UC缺乏特效治疗药物,患者常因为并发症、手术、激素耐药或依赖问题而痛苦异常、造成患者严重的经济、家庭负担。UC在国外十分常见,我国UC发病率和患病率也非常高,且呈现逐年增加的态势。由于UC的病因和发病机制十分复杂,因而临床缺乏特异性治疗药物,部分患者因缺乏有效治疗而伴随终身,患者的生活质量已经受到严重影响。目前,针对UC的治疗药物主要有肾上腺皮质激素、水杨酸类、免疫抑制剂等,这些药物因为具有副反应多、停药后易复发,部分顽固性病例疗效不理想等缺点,限制了其在临床的使用。
中医药治疗UC具有副反应少、价格低廉、疗效显著、无依赖性、多靶点整体调节、复发率低、治病求本以及远期疗效稳定等优势,具有较好的深入研究与应用开发价值,受到消化内科专家的青睐。中医药防治UC的机理研究亦是近年来研究者追踪的前沿热点。目前,在中医药防治UC的实验研究方面,医家多偏重从“湿热”病机入手,以“清化湿热”立法,对治疗泄泻的经典方,如“白头翁汤”、“芍药汤”、“参苓白术散”等进行了深入研究,取得了诸多成果。但缺乏对UC“肝郁脾虚”病机及“疏肝健脾法”的探讨。根据临床所见及证候分布和治法研究,发现“肝郁脾虚证”是UC的重要证候,“疏肝健脾法”亦是治疗UC的重要方法,尤其是精神情绪因素“肝郁”既可能是UC发病的始动因素,亦可能是UC病情加重或缠绵难愈的重要原因。治则治法是连接病机和方药疗效的核心环节,从“肝郁脾虚”病机视角研究“疏肝健脾法”治疗UC的疗效机制和作用靶点,不仅可以拓展中医药治疗UC的思路,揭示中医治法的科学内涵,亦可为开发防治UC的特效中成药提供理论和实验依据,所以本研究具有较好的应用前景和科学意义、现实意义。痛泻要方出自《丹溪心法》,由炒白术、炒白芍、防风、陈皮四味药组成,功能疏肝健脾,是治疗肝郁脾虚所致腹泻的经典方。回顾并研究古今近10年文献,发现临床运用痛泻要方或者痛泻要方的加减方治疗UC取得良好疗效的报道甚多,有较好的临床基础,但从实验角度研究其治疗UC的作用机理却鲜有报道。基于“肝郁脾虚证”是UC的重要证型,“肝郁脾虚”是UC的重要病机,“疏肝健脾法”是治疗UC的重要治法的认识,结合国内外鲜有研究“疏肝健脾法”治疗UC的作用机制,本研究以“疏肝健脾法”为指导,选用“疏肝健脾法”的代表方痛泻要方,针对UC“肝郁脾虚”基本病机,运用分子生物学实验技术,从基因和蛋白表达水平揭示痛泻要方治疗UC的分子机制,为其临床广泛运用提供实验依据。
研究方法：
本论文研究分为理论研究、实验研究两个部分。理论研究部分是在系统整理中医学对UC认识古今相关文献的基础上,结合现代医学对UC的研究进展,重点探讨了UC的中医病因病机,UC的免疫学发病机制,溃疡性结肠炎的证候分型、治法的分布规律,疏肝健脾法治疗UC的现状及本论文研究的主要思路。实验研究部分首先采用TNBS/乙醇灌肠法复建UC大鼠模型,在造模的不同时间段采用RT-PCR及ELISA法、免疫组化技术动态观察大鼠结肠组织NF-κB p65、PAR-γ、ICAM-1及血清TNF-α、IL-1β的动态表达、探讨了其在UC发病中的作用。其次是研究采用TNBS/乙醇灌肠+束缚法+饮食失节的复合方法建立大鼠肝郁脾虚型UC模型,并给予痛泻要方干预治疗,采用RT-PCR、免疫印迹及ELISA法检测其对UC大鼠结肠组织中PPARγ、NF-κB p65、ICAM-1表达以及血清中IL-1β、TNF-α水平的影响,一方面为治疗UC寻找新的作用靶点,另外一方面是从分子水平进一步探讨疏肝健脾法治疗UC作用机理。
研究结论及意义
1. TNBS/乙醇灌肠法可成功建立UC大鼠模型,肉眼观察及光镜镜观察均出现明显的炎症、溃疡。且结肠损伤随着造模时间不同呈现动态变化趋势,其中以3d和7d的病变最为严重,14d和21d天则炎症和溃疡有所修复。
2.在UC模型的急性期,结肠组织中PPAR-γ表达显著降低,慢性期PPAR-γ表达略有升高,但仍明显低于空白组。UC模型的急性期NF-κB p65、ICAM-1表达显著升高,慢性期,NF-κB p65、ICAM-1表达略有降低,但仍明显高于空白组。
3.促炎因子TNF-α、IL-1β和抗炎因子IL-4的平衡参与了UC的发生、发展。
4. PPAR-γ的表达与结肠组织损伤程度、IL-1β、TNF-α、NF-κB p65、ICAM-1的表达之间呈不同程度的负相关。
5.UC的发生与发展与PPAR-γ的表达受抑密切相关,上调PPAR-γ的表达有望成为UC治疗新靶向。
6.肝郁脾虚是UC的重要病机,肝郁脾虚证是UC的重要证候类型,疏肝健脾法是治疗UC的重要治法。
7.痛泻要方对肝郁脾虚型UC模型大鼠结肠组织具有良好的保护和修复作用,其分子机制可能是上调PPAR-y mRNA及蛋白表达,抑制结肠组织ICAM-1、 NF-κB p65mRNA及蛋白表达、抑制血清IL-1β、TNF-α的表达,从而减轻结肠炎症反应,起到治疗UC的作用。痛泻要方可能具有PPAR-γ激动剂的效用。
Purpose and Significance
Ulcerative colitis (uleerativeeolitis, UC) is a kind of unknown etiology, mainly involving the rectum and sigmoid colon mucosa and submucosa of the superficial, nonspecific inflammatory disease of digestive tract disease, can be extended to the descending colon, the transverse colon, minority can affects the colon, is difficult to cure, often recurrent, is considered to be precancerous lesions of the colon cancer, World Health Organization has been listed it as one of the modern difficult to treat. Modern medicine to UC is lack of a specific treatment, patients often bearing complications, surgery, hormone resistant or dependent abnormal pain, causing severe economic and family burden. Ulcerative colitis is quite common in Western countries, According to the ulcerative colitis-related documents and statistics the number of hospital cases show that its incidence is increasing year by year. Due to the complexity of the pathogenesis of UC, the cause is not yet very clear, due to the lack of effective treatment and specific clinical drug, for some patients accompanied by lifelong with abnormal pain, have serious impact on people's quality of life. At present, Drugs for UC are often salicylic acid, adrenal corticosteroids, immunosuppressants, etc. Most of them are easy to relapse after treatment, long-term medication side effects, for some stubborn cases, the effect is not ideal shortcomings.
In recent years, Chinese medicine in the treatment of UC achieved more satisfactory results, and has little side effects, low recurrence rate and long-term efficacy advantage with better research and development value, favored by the Department of Gastroenterology experts, it is the tracked hotspots in recent years that the Mechanism research on Traditional Chinese Medicine to UC. At present, mechanism on Traditional Chinese Medicine to treatment UC, physicians more emphasis to start from the "Shire" pathogenesis and treatment of diarrhea classic recipe of the "Qinghuashire", such as "Pulsatilla soup","Peony soup","Shenlingbaishu powder" made a lot of achievements. But, according to clinical diagnosis, stagnation and spleen deficiency is important pathogenesis of UC,"Shuganjianpi" is an important method for the treatment of UC, especially the mental factor "liver depression" is probably UC incidence initiating factor, or hard to be cured reasons. The therapeutic principle is the core aspects of connected to the pathogenesis and recipe efficacy, clarify its efficacy mechanism and target of the treatment of UC's efficacy, from perspective of stagnation and spleen deficiency to study curative effect mechanism of "Shuganjianpi" treatment of UC, can not only expand the idea of Chinese medicine treatment of UC, revealing the scientific connotation of TCM treatments, also provide theoretical support for the development of prevention and treatment of UC proprietary Chinese medicines, all in all, this study has good application prospects and scientific significance and practical significance. Tong Xie Yao Fang from the "Danxi Experiences", composed of four herbs of fried Baizhu, fried Baishao, Fangfeng and Chenpi, its function is Shuganjianpi, it is the classic recipe for diarrhea raised by liver depression and spleen. Reviewed and studied nearly10years ancient and modern literature, it is found that the clinical use Tongxieyaofang or it's extend recipe for treatment of UC achieved good effect, with good clinical basis, but it is rarely reported of treatment UC mechanism from the experimental perspective. Liver depression and spleen deficiency syndrome is important UC pattern of syndrome, stagnation and spleen deficiency is an important pathogenesis of UC,"Shuganjianpi" is the important treatment of UC, combined with domestic and international fresh research on "Shuganjianpi "treatment mechanism of UC, this study as guide of the "Shuganjianpi" treatment, choice its representative recipe of Tongxieyaofang, aim at basic pathogenesis of UC stagnation and spleen deficiency, focusing on the use of the experimental techniques of molecular biology, from geneand the level of protein expression reveal the TongxieYaofang treatment of the molecular mechanisms of UC, provided experiment basis for the clinical extensive application.
Research Methods
This thesis is divided into two parts, theoretical and experimental studies. The theoretical part finishing medical UC understanding of the basis of the ancient and modern literature, combined with the progress of modern medicine on UC's research, focuses on TCM etiology and pathogenesis of UC, immunology for UC, UC syndrome type, conquer the logistic regression, the main idea of the treatment of the UC status quo and the thesis Shuganjianpi treatment. First, study part apply the TNBS/ethanol enema rehabilitation UC rat model of experimental, in the modeling of different time periods by RT-PCR, Western blot and ELISA, immunohistochemistry technology dynamic observation of rat colon tissue of PPAR-γ, NF-κB p65, ICAM-1and serum IL-1β, TNF-α, dynamic expression, and to explore its role in the pathogenesis of UC. Followed by research to establish the rat liver depression and spleen UC model TNBS/ethanol+binding method+diet disloyal composite method and treatment to give TongxueYaofang intervention, observation of UC colon tissue of PPARγ and NF-κB p65, ICAM-1content and the level of serum IL-1β, TNF-α, on the one hand, looking for a new role in the treatment of UC target, other hand, from the genetic level to further explore the mechanism of action of the Shuganjianpi treatment of UC, to provide a theoretical basis for its clinical application and development of new compound Chinese medicine.
Conclusions and Significance
a. TNBS/ethanol enema can be successfully established rat model of UC, observation from naked eye and microscopic, all showed inflammation and ulcers, and colon injury are dynamic modeling time trend, which is most severe lesions3d and7d,14d and21d days, some repair of the inflammation and ulceration would be appear.
b. In the acute phase of the UC model, PPARγ expression in colonic tissue was significantly reduced, the chronic phase PPARγ expression slightly elevated, but still lower than the blank group. UC model of the acute phase of NF-κB p65and ICAM-1expression was significantly increased in the chronic phase of NF-κB p65, ICAM-1expression slightly reduced, but still significantly higher than the blank group.
c. Proinflammatory cytokines TNF-α, IL-1β and anti-inflammatory cytokines IL-4balance involved in the occurrence of UC development.
d. PPAR-γ expression and colon tissue injury, IL-1β, TNF-α, NF-κB of p65, ICAM-1expression was negative correlation of different.
e. The occurrence and development of UC inhibited the expression of PPARγ is closely related to raised expression of PPAR-γ is expected to become the new targeted treatment of UC.
f. Liver stagnation and spleen deficiency is an important pathogenesis of ulcerative colitis; stagnation and spleen deficiency is important pathogenesis of UC,"Shuganjianpi" is an important method for the treatment of UC
g. Tong Xie Yao Fang has protection and repair function for the model of stagnation and spleen deficiency UC colon tissue, the molecular mechanism is up regulated PPAR-y mRNA and protein expression, inhibition of the colonic tissues ICAM-1, NF-κB p65mRNA and protein expression, suppression of serum IL-1β and TNF-α expression, so as to reduce the inflammatory reaction, and play a role in the treatment of UC. The TongXieYaofang may have PPAR agonist's utility.
引文
[1]刘凤斌,李筱颖.溃疡性结肠炎患者生存质量研究现状与展望[J].世界华人消化杂志,2011,19(5)：498-504.
[2]桑力轩,刘汉立,姜敏.溃疡性结肠炎发病机制研究进展[J].世界华人消化杂志2007,15(20)：2249-2254.
[3]周婷婷,仝巧云.溃疡性结肠炎发病机制的研究进展[J].胃肠病学和肝病学杂志,2012,21(12)：1163-1166.
[4]纪桂贤,郑岳.溃疡性结肠炎治疗进展[J].中国误诊学杂志,2011,11(13)：3048-3051.
[5]樊慧丽,陈玉梅.溃疡性结肠炎的发病机制和治疗进展[J].中国全科医学,2012,15(1)：228-231.
[6]溃疡性结肠炎中医诊疗共识意见[J].中华中医药杂志(原中国医药学报),2010,25(6)：891-894.
[6]苗新普, 欧阳钦,韦红,黄咏东.溃疡性结肠炎组织中5-LOX、PPARγ和NF-κBP65的表达及意义[J].实用医学杂志,2011,27(10)：1757-1760.
[7]Atreya I, Atreya R, Neurath M F. NF-kappaB in inflammatorybowel disease [J]. J Intern Med,2008,263 (6):591-596.
[8]Jupp J, Hillier K, Elliott D H, et al. Colonic expression ofleukotriene-pathway enzymes in inflammatory bowel diseases[J]. Inflamm Bowel Dis,2007,13 (5):537-546.
[9]Katz JA, Itoh J, Fiocchi C. Pathogenesis of inflam-matory bowel disease. Curr Opin Gastroenterol 1999;15:291-297.
[10]Neurath MF, Meyer zum Buschenfelde KH. Protec-tive and pathogenic roles of cytokines in inflamma-tory bowel diseases[J]. J Investig Med 1996; 44:516-521.
[11]李春雷,陈治水.白介素在溃疡性结肠炎发病机制中的研究进展[J].现代消化及介入诊疗,2008,13(2)：146-149.
[12]张文俊,许国铭,李兆中,等.血清白细胞介素1p与溃疡性结肠炎的关系[J].第二军医大学学报.2002,23(6)：1345-1347.
[13]庞艳华,郑长青Th1/Th2细胞亚群与炎症性肠病的关系[J].世界华人消化杂志,2004,12(5)：1922-1924.
[14]口锁堂,吴焕淦,施达仁.白介素与溃疡性结肠炎[J].世界华人消化杂志,2006,14(3)405-411.
[15]王新月,杨莉莉,王雪茜,等.溃结饮不同给药途径对溃疡性结肠炎大鼠前炎性细胞因子表达的影响[J].中国中西医结合消化杂志.2006,14(3)：351-354.
[16]Tian L, Huang YX, Tian M,et al. Downregulation of elec-troacupuncture at ST36 on TNF-alpha in rats with ulcerativecolitis[J]. World J Gastroenterol,2003,9(5):1028-1033.
[17]陈垦,梁坚,周宇,等.溃疡性结肠炎病人血清SIL IR和TNF-α水平的变化及意义探讨[J].中国肛肠病杂志,1999,19(7)：9-11.
[18]李琪佳,徐敏,宫恩聪,等.细胞因子与溃疡性结肠炎[J].中国煤炭工业医学杂志,2001,4(6)：411-412.
[19]秦越人,《难经》[M].人民卫生出版社,1979.
[20]郭霭春,《黄帝内经素问语译》[M].人民卫生出版社,1995.
[21]龚廷贤,《寿世保元》,《龚廷贤医学全书》[M],中国中医药出版社,1999,564.
[22]张仲景,(宋本新辑)重庆市中医学会编注,《伤寒论》[M].重庆人民出版社,1955,97,108.
[23]巢元方,《诸病源候论》[M].人民卫生出版社影印本,1955.
[24]孙一奎,《赤水玄珠》,《孙一奎医学全书》[M].中国中医药出版社,1999,193,202.
[25]张景岳,《景岳全书》[M].人民卫生出版社,1991.
[26]陈言,《三因极一病证方论》[M].人民卫生出版社,1957.
[27]严用和,《济生方》,《古今图书集成医部全录》[M].人民卫生出版社,1962,864.
[28]陈十铎,《辨证录》[M].人民卫生出版社,1989,429,438-439.
[29]林佩琴,《类证治裁》[M].中医综合类名著集成.华夏出版社,1997.
[30]吴佳,李胜吾,张镭潇,等.从《黄帝内经》辨析溃疡性结肠炎的病因病机及预后[J].山东中医杂志2012,31(5)：309-310
[31]朱立,王新月.溃疡性结肠炎病因病机理论探讨[J].吉林中医药2010,30(1)：10-11.
[32]肖培新.溃疡性结肠炎病因病机认识及诊治体会[J].中国民间疗法,201],19(7)：5-6.
[33]赵景明.溃疡性结肠炎病因病机认识进展[J].中医学报,2010,23(5)：23-25.
[34]姜桂宁.溃疡性结肠炎病因病机探讨[J].山东中医杂志2008,27(4)：219-223
[35]吴家玮.溃疡性结肠炎病因病机特点与中医辨治思路[J].内蒙古中医药,2011,53(6)：7-9.
[36]王新月,田德禄.溃疡性结肠炎病因病理特点与中医辨治思路对策[J].北京中医药大学学报,2007,30(8)：554-559
[37]李梅,张苏闽.溃疡性结肠炎病因分析及预防[J].中医学报,2012,27(173)：1343-1345.
[38]姜杰新.溃疡性结肠炎病因及发病机制的研究进展[J].医师进修杂志,2004,27(12)：51-520.
[39]韩捷.溃疡性结肠炎病因及中医研究进展[J].中医药信息,2002,19(5)：4-6
[40]王丽.溃疡性结肠炎病因及中医证治浅析[J].中医药学刊,2004,22(12)：2778-2779
[41]唐容川,《血证论》[M].上海人民出版社,1977.
[42]张昶,《百病问对辨疑》,《中医临床经典》[M].上海中医药大学出版社,1997,483-486.
[43]王纶,《明医杂著》,《古今图书集成医部全录》[M].人民卫生出版社,1962,881,883.
[44]赵估,《圣济总录》[M].人民卫生出版社,1962.
[45]汪机,《医学原理》,《汪石山医学全书》[M].中国中医药出版社,1999,695-696.
[46]戴宝林.溃疡性结肠炎病因病机探讨及辨治体会[J].天津中医学院学报,2001,20(3)：37-38
[47]林燕,李建.基于“毒损肠络”理论的溃疡性结肠炎复发病机探微[J].中国临床医生,2012,40(11)：9-11.
[48]焦君良,要丽瑛,李士军,等.从痈论治溃疡性结肠炎初探[J].中国中西医结合脾胃杂志,2000,8(2)：100-103.
[49]曹婷婷.溃疡性结肠炎不同病情分期病机证治探析[J].江西中医药,2012,43(355)：7.
[50]段永强,梁玉杰,成映霞,等.论“肝郁脾虚”病机在溃疡性结肠炎中的病理意义及其相关性[J].辽宁中医药大学学报,2007,9(5)3-4.
[51]韩捷.脾虚湿热型溃疡性结肠炎的临床特点[J].中国实验方剂学杂志,2010,16(10)：191-192.
[52]刘敏,崔红生.溃疡性结肠炎的病机演变规律及用药体会[J].河北中医学院学报,1995,10(3)：16-17.
[53]贺海辉,沈洪,叶柏.溃疡性结肠炎活动期的病机与治法[J].南京中医药大学学报,2012,28(6)504-512.
[54]王希利,彭艳红,孙明祎,等.溃疡性结肠炎痰瘀病机要素探析[J].中华中医药学刊,2007,25(4)：720-721.
[55]陈江.溃疡性结肠炎中医病机演变及证治探讨[J].新中医,2005,37(4)：11-12
[56]范恒,邱明义,段雪理,等.肠四方治疗溃疡性结肠炎病机探讨[J].贵阳中医学院学报,2004,26(4)：17-19.
[57]李恒谋.脾虚型慢性结肠炎、溃疡性结肠炎的病机特点及治疗规律[J].华人消化杂志,1998,6(8)：726-728.
[58]中华中医药学会编著.中医内科常见病诊疗指南·西医疾病部分[M].中国中医药出版社,2008：107-110.
[59]马登斌,晓敏.溃疡性结肠炎中医药治疗的点滴体会[J].医学信息,2010,20(3)：409-410.
[60]倪海.辨证论治溃疡性结肠炎58例[C].甘肃省中医药学会2010年会员代表大会 暨学术年会论文汇编,2011.
[61]范素琴,李玉琢.辨证治疗溃疡性结肠炎46例[J].中医临床研究,2011,3(13)：83-84.
[62]曹景龙.溃疡性结肠炎中医辨证治疗36例分析[J].中外医疗,2010,31(2)：134.
[63]赵克华.辨证分型治疗溃疡性结肠炎[J].中医学报,2010,2(25)：329-330.
[64]张广业,邢继霞,党传玲.辨证论治配合灌肠治疗溃疡性结肠炎67例[J].新中医,2005,37(2)：69-70.
[65]黄文武.中医辨证论治治疗慢性溃疡性结肠炎56例[J].井冈山学院学报,2006,27(2)：122-123.
[66]安雪峰,赵继国,任茜.中医辨证分型治疗慢性结肠炎82例[J].四川中医,2005,23(9)：63-64.
[67]陈剑明,张声生,崔超.基于经验辨证的溃疡性结肠炎常见证候及证候要素的临床研究[J].北京中医药2011,30(6)：418-420.
[68]张会珍,刘建平.许占民教授治疗慢性非特异性溃疡性结肠炎临床经验撷要[J].新中医,2002,34(11)：14-16.
[69]张洪俊.加味痛泻要方治疗慢性结肠炎32例[J].陕西中医,1995,16(7)： 302.
[70]程卫军.疏肝健脾法治疗溃疡性结肠炎的临床观察[J].中国中西医结合杂志,2001,2](1)：34.
[71]田德禄,田海河.慢性非特异性溃疡性结肠炎中医研究述评[J].北京中医药大学学报,1994,17(6)：2-6.
[72陈业强,凌江红.从脑肠肽进行肝郁证与功能性消化不良病证结合研究的思路[J].中医杂志,2006,47(10)：784.
[73]衣蕾,聂丹丽.脾虚证的现代医学研究进展[J].陕西中医学院学报,2005,28(3)：59.
[74]曹小玉,杨智梅,彭成. 四君子颗粒抗脾虚动物胃肠细胞损伤的研究[J].成都中医药大学学报,2000,23(3)：32.
[75]毛海燕. 肝郁证大鼠肝线粒体膜流动性、血浆胃动素及血清胃泌素的变化及意义[J]. 福建中医药,2003,34(3)：42.
[76]肖桂林. 肝郁脾虚证实验诊断指标的研究[J]. 湖南中医学院学报,1998,18(2)：4.
[77]骆天炯.健脾疏肝法对肠易激综合征血浆及粘膜B内啡肽的调节作用[J].中国中西医结合杂志,2003,23(8)：616.
[78]黄穗平.从肝论治肠易激综合征[J]. 中医杂志,1990,31(3)：31.
[79]周玫.非特异性溃疡性结肠炎中西医结合诊治研究进展[J].中西医结合杂志,1988, 8(3)：184.
[80]许晓丽,王凤仪.溃疡性结肠炎中医证素分布及组合规律的文献分析[J].亚太传统医药,2011,7(5)：131-132.
[81]张北平,刘思德,李明松,等.溃疡性结肠炎内镜分型、黏膜织学分期与中医虚实证候的相关性研究[J].中国消化内镜,2008,2(3)：5-8.
[82]周秀丽,邢军,常丽丽.溃疡性结肠炎外周血黏附分子表达增高及其在中西医结合辨证分型相关性研究中的意义[J].河北医药,2008,30(7)：958-959.
[83]徐璠.培土抑木法在防治结肠炎中的应用[J].陕西中医,2006,27(12)：1548-1549.
[84]刘建波. 痛泻要方加减治疗肝郁脾虚型慢性溃疡性结肠炎28例[J].安徽中医临床杂志,2002,14(4)：175-176.
[85]韩建庆,范宇.健脾疏肝活血法治疗慢性溃疡性结肠炎47例[J].中医临床研究,2010,2(5)：42-43.
[86]邹信字.疏肝健脾法治疗慢性结肠炎32例[J].湖南中医药导报,2003,9(4)：27-28.
[87]程卫军.疏肝健脾法治疗溃疡性结肠炎的临床观察[J].中国中西医结合杂志,2001,21(1)：34-36.
[88]刘红芬,常丽丽,周晓娜,等.不同中医证型溃疡性结肠炎患者血清干扰素-γ和白细胞介素-4水平的变化[J].中国医药导刊,2008,10(6)：900-901.
[89]常丽丽,张淑梅,李光难,等.不同中医证型溃疡性结肠炎患者免疫球蛋白水平的研究[J]. 中国医药导刊,2008,10(8)：1221-1224.
[90]陈俊玲,曾斌.不同中医证型维吾尔族溃疡性结肠炎患者免疫球蛋白水平的研究[J]. 现代中西医结合杂志,2009,18(31)：3815-3816.
[91]王丽娜,范颖,卢健,林庶茹.四逆散干预实验性溃疡性结肠炎的药效学研究[J].中医研究,2011,24(2)：11-13.
[92]刘学芳,丁国萍. 疏肝健脾法治疗慢性结肠炎28例[J].社区医学杂志,2007,5(22)：27-28.
[93]王正君,张海燕. 结肠汤治疗溃疡性结肠炎62例[J].陕西中医,2005,26(1)：37-38.
[94]李雅萍.运用调和肝脾法治疗慢性结肠炎[J]. 包头医学,2007,31(4)：226.
[95]王玉杰,谢鸣.疏肝方、健脾方、疏肝健脾方对肝郁脾虚证模型大鼠IL-2、IL-6及T淋巴细胞增殖率的影响[J].北京中医药大学学报,2009,32(6)：398-401.
[96]叶仕.疏肝健脾法对肝郁脾虚型溃疡性结肠炎患者肠黏膜ICAM-1、VCAM-1表达的影响[C]／/2006年广东省中医、中西医结合脾胃消化病学术会议论文汇编.广州：2006年广东省中医、中西医结合脾胃消化病学术会议,2006： 274-279.
[97]陈俊玲,曾斌.不同中医证型维吾尔族溃疡性结肠炎患者免疫球蛋白水平的研究[J].现代中西医结合杂志,2009,18(31)：3815-3816.
[98]郭军雄.中医对溃疡性结肠炎的认识[J].中医研究,2010,23(10)：9-10.
[99]李云.溃疡性结肠炎治疗心法[J].中医研究,2009,22(7)：57-59.
[100]李云海,张雪荣.陈国权教授治疗溃疡性结肠炎经验[J].中医研究,2006,19(7)：4-48.
[101]顾立刚,郭学志.疏肝健脾方对溃疡性结肠炎肝郁脾虚证大鼠结肠溃疡的影响[J].北京中医药大学学报,2000,23(4)：24-26.
[102]秦震声,张燕生.疏肝健脾法对溃疡性结肠炎肝郁脾虚模型大鼠的治疗作用研究[J].中医研究,2007,20(5)：13-15.
[103]赖象权,何本求,周宏燕,等.侗药五味止泻汤对溃疡性结肠炎大鼠血清IL-1, IL-10的影响[J].中国实验方剂学杂志,2012,18(17)：227-230.
[104]梁兴伦,吴闯,姜在龙.溃结2号方对溃疡性结肠炎大鼠溃疡组织中IL-1β及IL-10mRNA表达的影响[J].广州中医药大学学报,2012,29(4)：397-400.
[105]陶弘武,柳越冬.溃结安康汤对溃疡性结肠炎大鼠结肠组织IL-1p的作用及蛋白表达的影响[J].辽宁中医杂志,2009,36(6)：1025-1027.
[106]陈淑娜,刘若丹.罗格列酮联合美沙拉嗪治疗溃疡性结肠炎对IL-1β、TNF-a的影响[J].广西医学,2011,3(4)：432-435.
[107]荣英蕊,刘建平,郎晓猛.泄浊解毒方对溃疡性结肠炎大鼠TLR2及IL-8、IL-1β影响的研究[J].四川中医,2012,30(5)：33-35.
[108]谢力,邢之华.三皮汤对小鼠溃疡性结肠炎模型IL-2和IL-10表达的影响[J].中国实验方剂学杂志,2009,15(9)：67-69.
[109]邹阳王,兴友杨,孝芳.溃疡性结肠炎大鼠IL-2、CD44、CD54的实验研究[J].江西医学检验,2002,20(5)：281-283.
[110]古学文.溃疡性结肠炎患者血清IL-2及sIL-2R浓度变化的研究[J].临东和实脸医学杂志,2003,2(3)：153-155.
[111]郭建生,湛扩,彭宇.肠炎愈片对大鼠溃疡性结肠炎血清白介素-2、一氧化氮的影响研究[J].湖南中医药大学学报,2007,27(6)：18-21.
[112]李桂贤,黄勇华,唐梅.加味柴芍六君颗粒对实验性溃疡性结肠炎大鼠T淋巴细胞亚群及白介素-2的影响[J],广西中医药,2007,30(4)：51-53.
[113]林巧嫦,廖博贤,黄飞娜.白细胞介素IL-4、IL-17在溃疡性结肠炎中的表达[J].中国医药科学,2012,2(16)：44-45.
[114]王小军,调解汤对大鼠溃疡性结肠炎肝郁模型血清中1L-4水平的影响[J].辽宁中医药大学学报,2009,11(3)：194-195.
[115]郝丽君,唐文君,郑荣娟.谷胺酰胺颗粒灌肠对溃疡性结肠炎患者IFN-γ、IL-4IL-8的影响及疗效观察[J].中华医院感染学杂志,2011,21(22)：4742-4744.
[116]黄芪多糖对溃疡性结肠炎大鼠血清IL-4、IL-5和IL-13水平的影响[J].贵阳中医学院学报,贵阳中医学院学报,2011,33(4)：23-25.
[117]王晓梅,郑世江,李静.溃结结合剂对溃疡性结肠炎大鼠IL-1β和IL-4的影响[J].山西中医学院学报,2006,7(5)：18-19.
[118]王雪茜,王新月.溃结饮2种给药途径对大鼠溃疡性结肠炎血清IFN-y和IL-4的影响[J].北京中医药大学学报,2010,33(7)：468-470.
[1]9]岳文杰,刘懿,徐薇,溃疡性结肠炎(UC)肠黏膜中IL-2、IL-4、IL-17和IL-10 的表达特点及其与疾病活动度的关系[J].复旦学报(医学版),2012,39(5)：454-457.
[120]卢健,于彩娜,马骥.四逆散对实验性溃疡性结肠炎大鼠IL-4的影响[J].中华中医药学刊,2011,29(4)：813-814.
[121]戴思思,董克礼.愈疡灌肠方治疗溃疡性结肠炎疗效及对血清IL-4 IL-10的影响[J].辽宁中医药大学学报,2010,12(2)：152-153.
[122]吴先哲,熊益群,邢国良.黄芪多糖对溃疡性结肠炎大鼠血清IL-4、IL-5和IL-13水平的影响[J].贵阳中医学院学报,2011,33(4)：23-25.
[123]宋爱玲TNF-a、IL-6、IL-8与溃疡性结肠炎严重程度相关研究[J].中国实用医药,2008,3(36)：3-5.
[124]厉洁,曲海霞,卫红军.溃疡性结肠炎患者炎症黏膜中IL-6、IL-23的表达及其临床意义[J].胃肠病学,2011,16(3)：164-165.
[125]马普伟,陈金泉,林锡芬.中医清热化湿法对溃疡性结肠炎患者血清TNF-a和IL-6的影响[J].江西中医学院学报,2010,22(1)：62-63.
[126]陈强妹,美沙拉嗪缓释颗粒对溃疡性结肠炎患者血清IL-6、TNF-α影响机制的研究[J].2011,49(36)：34-35.
[127]刘青梅,韩辅,陈曦.肠康饮对溃疡性结肠炎大鼠血清IL-6、IL-10的影响[J].世界中西医结合杂志2008,3(5)：266-268.
[128]潘勇,舒洪权,颜景颖.结肠康Ⅰ号对溃疡性结肠炎大鼠血清IL-6、IL-10的影响[J].中国民族民间医药,2011,3(20)：86-89.
[129]王觅柱,邬彩虹,陈吉.溃疡性结肠炎患者血清IL-1β、TNF-α和IL-10的表达及其意义[J].国际消化病杂志2009,29(5)：362-366.
[130]孙建华,吴闯,姜在龙.溃结2号方对溃疡性结肠炎大鼠溃疡组织中TNF-α及其mRNA表达的影响[J].上海中医药杂志,2012,46(4)：65-68.
[131]金纯,李霞,金可可.葛仙汤对溃疡性结肠炎大鼠结肠TNF-α和iNOS表达的干预作用[J].医学研究杂志2012,41(9)：115-118.
132]谭彬,赵己未.溃疡性结肠炎患者血清IL-13、IL-8的水平变化及意义[J].临床医学工程,2012,19(4)：581-582.
[133]刘力,张欢,马文军.马齿苋水煎剂对溃疡性结肠炎小鼠结肠组织中IL-8、IL-10表达的影响[J].辽宁中医药大学学报,2011,13(5)：18-20.
[134]姚民武,李保良,黄水清.乌梅丸对溃疡性结肠炎患者血清TNF-a、IL-6及IL-8含量的影响[J].医学信息,2010,8：2188-2189.
[135]周红光,陈海彬,徐肇敏.溃克灵对溃疡性结肠炎模型大鼠血清IL-8含量的影响[J].南京医科大学学报,2009,29(4)：488-490.
[136]李进,杨锐,邓豫IL-1β、IL-10在大鼠溃疡性结肠炎模型中的表达[J].,南昌大学学报,2010,50(12)：41-44.
[137]李贞娟,张彩凤,韩宇.IL-10单核营酸多态性与溃疡性结肠炎的相关性研究[J]. 山东医药,2012,52(13)：49-51.
[138]梁兴伦,吴闯,姜在龙.溃结2号方对溃疡性结肠炎大鼠溃疡组织中IL-1p及IL10 mRNA表达的影响[J].广州中医药大学学报,2012,29(4)：397-400.
[139]陶弘武,柳越冬.溃结安康汤对溃疡性结肠炎大鼠结肠组织IL-10的作用及蛋白表达的影响[J].中华中医药学刊,2009,27(6)：1257-1259.
[140]谢力,邢之华,蒋荣鑫.三皮汤对小鼠溃疡性结肠炎模型IL-2和IL-10表达的影响[J],中国实验方剂学杂志,2009,15(9)：67-69.
[141]张志杰,谢胜,马高峰.中医药对溃疡性结肠炎患者血清IL-8、IL-10的影响[J].陕西中医,2011,32(5)：566-568.
[142]贾长河,许泼实,康谊.溃疡性结肠炎患者血清IL-8、IL-10、TNF-a的水平及临床意义[J].中华实用诊断与治疗杂志,2008,22(8)：574-577.
[143]魏艳静,卞红磊.溃疡性结肠炎大鼠肠黏膜PPARy的表达[J].天津医药,2004,32(9)：568-569.
[144]Bassaganya-Riera J,Reynolds K,Martino-Catt S,et al.Activation of PPAR gamma and delta byconjugated linoleic acid mediates protection from experimental inflammatory bowel disease.Gastroenterology,2004,127(3):777-791
[145]Willson TM,Brown PJ,Sternbach DD,et al.The PPARs:from orphan receptors to drug discovery.Med Chem,2000,43(4):527-550.
[146]Bassaganya-Riera J,Reynolds K,Martino-Catt S,et al.Activation of PPAR gamma and delta byconjugated linoleic acid mediates protection from experimental inflammatory bowel disease.Gastroenterology,2004,127(3):777-791.
[147]柯希权,王启之,燕善军,等.溃疡性结肠炎大鼠结肠黏膜中MMP-3和PPAR-y的表达及其意义[J].胃肠病学和肝病学杂志,2009,18(9)：824-827.
[148]张燕,欧阳钦,陈代云PPAR-y在溃疡性结肠炎粘膜中的表达[J].中华消化内镜杂志,2002,19(2)：81-83.
[149]卞红磊,魏艳静,赵发.柳氮磺胺吡啶对溃疡性结肠炎大鼠结肠黏膜上皮PPARy表达的影响[J].广东医学,2004,25(1])：1258-1259.
[150]苗新普,欧阳钦,韦红COX-2. PPAR-y和NF-κB p65在溃疡性结肠炎组织中的表达及意义[J].世界华人消化杂志,2010,18(25)：2660-2665.
[151]梁红亮,欧阳钦.过氧化物酶体增生物激活受体-γ在小鼠嗯唑酮结肠炎中作用的研究[J].胃肠病学,2007,12(2)：101-105.
[152]周静平,邓长生.罗格列酮对大鼠溃疡性结肠炎的疗效及其机制[J].临床消化病杂志.2006,18(2)：84-85.
[153]Sen P,Wallet MA,et al.Apoptotic cells induce Mer Tyrosinekinase-DepEndent blockade ofNF-kappaB activation in dendritic cells.Blood,2007,109(2):65-660.
[154]陈维雄,陈金联,达炜,等.P选择素和ICAM-1对小鼠溃疡性结肠炎的研究[J].世界华人消化杂志,2002,10(6)：722-724.
[155]施征,张卫,吴焕,金艾灸对溃疡性结肠炎结肠粘膜IL-8、ICAM-1及其mRNA 表达的影响[J].中医药学刊,2004,22(6)：1011-1013.
[156]张运贵,张瑞玲,黄咏梅,等.二丙酸倍氯米松治疗溃疡性结肠炎的疗效及对P-选择素、ICAM-1表达影响研究[J].临床消化病杂志,2008,23(3)：176-178.
[157]杜群,李红,王汝俊.溃结灵对溃疡性结肠炎大鼠结肠粘膜[J].广州中医药大学学报,2008,25(3)：229-231.
[158]王小琴,孔超美,张予蜀.美沙拉嗪缓释颗粒(艾迪莎)对溃疡性结肠炎患者肠黏膜组织病理学改变及血清ICAM-1水平的影响[J].实用临床医药杂志,2010,14(17)：66-68.
[159]郑红斌,胡鸿毅,马贵同.清肠栓对溃疡性结肠炎实验大鼠ICAM-1表达的影响[J].浙江中医学院学报,2004,28(6)：44-46.
[160]李海龙,程小丽,董晓丽.NF-κB和ICAM-1在溃疡性结肠炎大鼠结肠中表达及中药干预的影响[J].中国老年学杂志,2011,9(31)：1594-1596.
[161]周红光,陈海彬,徐肇敏,于成功.溃克灵对溃疡性结肠炎大鼠模型结肠黏膜ICAM-1基因表达的影响[J].南京中医药大学学报,2009,25(3)：216-218.
[162]赵晓霞,郭胜,李宝鹤,虎勤.芍药汤对溃疡性结肠炎大鼠ICAM-1、TNF-α、IL-10影响的实验研究[J].中国中医药科技,2008,15(3)：174-176.
[163]王雪冰,安新茹.肠康灵汤对溃疡性结肠炎大鼠ICAM-1的影响[J].西部中医药,2011,24(7)22-24.
[164]张竹,方步武,朱爱江,等.痛泻要方的抗炎作用研究[J].中药药理与临床,25(4)：1-3.
[165]范恒,邱明义,梅家俊,等.理肠四方对溃疡性结肠炎大鼠组织细胞因子TNF-a、 IL-6、IL-8、IL-10的影响[J].中医药学刊,2004,22(9)：1624-1627
[166]胡旭光,利红宇.痛泻要方对肝郁脾虚型溃疡性结肠炎动物模型的治疗作用[J]..广东药学院学报,2004,20(1)：40-41.
[167]陈文莉,郭良集,莫宁,等.加味痛泻要方抗炎镇痛作用的实验研究[J].中国实验方剂学杂志,2007,13(5)：20-27.
[1]Sutherland L, MacDonald JK. Oral 5-aminosalicylicacid for induction of remission inulcerative colitis.Cochrane Database Syst Rev 2003; (3):CD000543
[2]Campieri M. New steroids and new salicylates ininflammatory bowel disease:a critical appraisal.Gut 2002; 50 Suppl 3:Ⅲ43-Ⅲ46
[3]Iacucci M, de Silva S, Ghosh S. Mesalazine in in-flammatory bowel disease:a trendy topiconceagain? Can J Gastroenterol 2010; 24:127-133
[4]Feagan BG, Macdonald JK. Oral 5-aminosalicylicacid for maintenance of remission in ulcerative coli-tis. Cochrane Database Syst Rev 2012; (10):CD000544
[5]Travis SP, Stange EF, Lemann M, Oresland T, Be-melman WA, Chowers Y, Colombel JF, D'HaensG, Ghosh S, Marteau P, Kruis W, Mortensen NJ,Penninckx F, Gassull M. European evidence-basedConsensus on the management of ulcerative colitis:Current management. J Crohns Colitis 2008; 2:24-62
[6]Marteau P, Probert CS, Lindgren S, Gassul M, TanTG, Dignass A, Befrits R, Midhagen G, RademakerJ, Foldager M. Combined oral and enema treatmentwith Pentasa (mesalazine) is superior to oral thera-py alone in patients with extensive mild/moderateactive ulcerative colitis:a randomised, double blind,placebo controlled study. Gut 2005; 54:960-965
[7]Kruis W, Kiudelis G, Racz I, Gorelov IA, Pokrot-nieks J, Horynski M, Batovsky M, Kykal J, BoehmS, Greinwald R, Mueiler R. Once daily versus threetimes daily mesalazine granules in active ulcer-ative colitis:a double-blind, double-dummy, ran-domised, non-inferiority trial. Gut 2009; 58:233-240
[8]Hussain FN, AjjanRA, KapurK, MoustafaM,Riley SA. Once versus divided dailydosing withdelayed-release mesalazine:a study of tissue drugconcentrations and standard pharmacokinetic pa-rameters. Aliment Pharmacol Ther 2001; 15:53-62
[9]Sandborn WJ, Korzenik J, Lashner B, Leighton JA,Mahadevan U, Marion JF, Safdi M, Sninsky CA,Patel RM, Friedenberg KA, Dunnmon P, Ramsey D,Kane S. Once-daily dosing of delayed-release oralmesalamine (400-mg tablet) is as effective as twice-daily dosing for maintenance of remission of ulcer-ative colitis. Gastroenterology 2010; 138: 1286-1296,1286-1296
[10]Dignass AU, Bokemeyer B, Adamek H, Mross M,Vinter-Jensen L, Borner N, Silvennoinen J, Tan G,Pool MO, Stijnen T, Dietel P, Klugmann T, VermeireS, Bhatt A, Veerman H. Mesalamine once daily ismore effective than twice daily in patients with qui-escent ulcerative colitis. Clin Gastroenterol Hepatol2009; 7:762-769
[11]Morris GP, Beck PL, Herridge MS, et al. Hapten-induced model of chronic inflammation and ulceration in the rat colon. Gastroenterology,1989,96(3):795-803
[12]郑礼,高振强,王淑仙.大鼠溃疡性结肠炎模型的实验研究[J].中国药理学通报,1998,14(4)：370-72
[13]郭振球,赵晓威.肝纤宁对肝郁脾虚大鼠的保肝抗纤作用[J].湖南中医学院学报,1998,18(2)：10-12
[14]韩秋艳.肝郁脾虚证动物模型的建立[J].贵阳中医学院学报,2001,23(3)：59-61
[13]顾立刚,郭学志,王庆国.大鼠溃疡性结肠炎肝郁脾虚证动物模型的研究[J].北京中医药大学学报,1999,22(2)：21-23
[15]湖南医学院第一附属医院中医基础理论研究室.肝郁脾虚的理论与实验研究[J].湖南医学院学报,1979,4(3)：131-143
[16]刘绍唐,陈道森,潘玲,等.穴位注射对实验性肝郁脾虚动物模型的影响[J].成都中医药大学学报,1995,18(3)：38-41.
[17]李艳彦,谢鸣,陈禹,等.肝郁脾虚证大鼠模型复制中的免疫系统变化[J].中华中医药杂志,2006,21(7)：428-429
[18]张芳艳,毛新民,武鸿莉,等.肝郁脾虚型溃疡性结肠炎大鼠的免疫学研究[J].新疆医科大学学报,2004,27(4)：367-369
[19]刘金玲,姚良权,聂路安.疏肝健脾治疗与肝郁脾虚因素刺激对大肠癌大鼠免疫功能变化的探讨[J].国际医药卫生导报,2006,12(3)：4-6
[20]唐已婷,陈家旭.束缚应激与中医肝的关系[J].中国医药学报,2002,17(2)：82-83
[21]李强.抗抑郁药及心理疗法在溃疡性结肠炎治疗中的作用[J].山东医药,2005,45(18)：56.
[22]石慧琳,应激对肠黏膜屏障功能的影响研究进展[J].国外医学消化病分册,2003,23(3)：164-167.
[23]邵枫.应激对免疫作用机制的研究进展[J].心理学动态,1999,7(3)：5.
[24]中华中医药学会脾胃病分会,溃疡性结肠炎中医诊疗共识意见[J],中华中医药杂志,2010,25(6)：891-895.
[25]路晓红,杨恩来,赵霞,等.溃疡性结肠炎免疫机制的研究进展[J].山西中医学院学报,2011,12(1)：66-68.
[26]李楠,王雪明,翟俊山,等.复方血竭对溃疡性结肠炎大鼠模型结肠组织细胞因子的调节作用[J],中国实验方剂学杂志,2008,14(1)：53-54.
[27]卢健,马骥,王丽娜,等.四逆散对实验性溃疡性结肠炎大鼠IL-1β的影响[J].中国实验方剂学杂志,2011,17(1)：103-105.
[28]Tjandra K, Le T, Swain M G. Experimental colitisattenuates development of toxin-induced cholangitis in rats[J]. Dig Dis Sci,2002,47:1216.
[29]邓辉,钦丹萍.中医药对溃疡性结肠炎细胞因子的干预研究[J].中国中西医结合消化杂志,2006,14(5)344-346.
[30]许欣,于成功.中医药治疗溃疡性结肠炎的实验研究[J].长春中医药大学学报,2012,28(1)：81-83.
[31]朱凌宇,顾贤,马贵同,等.三七提取物对三硝基苯磺酸诱导溃疡性结肠炎大鼠结肠血管生成的研究[J].中国中西医结合消化杂志,2008,16(2)：99-102.
[32]陈百齐,季成春,刘德龙,等.中医药治疗溃疡性结肠炎研究概况[J].实用中医内科杂 志,2012,26(3)：96-98.
[33]余欣,邱明义,胡继鹰,等.乌梅丸对溃疡性结肠炎大鼠肠组织核转录因子-κB及细胞间黏附分子1的影响[J].中国中西医结合消化杂志,2008,16(3)：172-174.
[34]赵晓霞,郭胜,李宝鹤.芍药汤对溃疡性结肠炎大鼠ICAM-1、TNF-α、IL-10影响的实验研究[J].中国中医药科技,2008,15(3)：174-176.
[35]周燕红,于皆平.银杏叶提取物对大鼠实验性结肠炎NF-κB和ICAM-1表达的影响[J],广东医学,2007,28(6)：889-891.
[36]柯希权,王启之,燕善军,等.溃疡性结肠炎大鼠结肠黏膜中MMP-3和PPAR-γ的表达及其意义[J]..胃肠病学和肝病学杂志,2009,18(9)：824-927.
[37]GillesS, MarianiV, BryceM, eta.l Pollen-derivedE1-phytoprostan-es signal via PPAR-ga mmaand NF-kappaB-dependent mechanisms[J]. J Immuno,l 2009,182(11):6653-6658.
[38]Duan SZ, UsherMG, Mortensen RM. PPARs:the vasculature, in-flammation and hypertension [J]. Curr Opin Nephrol Hypertens,2009,18(2):128-133.
[39]RousseauxC, Desreumaux P. The peroxisome-proliferator-activatedgamma receptor and chronic inflammatory bowel disease (PPARgam-ma and IBD) [J]. J Soc Bio,l 2006,200(2): 121-131.
[40]Adachi M,Kurotani R,Morimura K,et al.Peroxisome proliferator ac-tivated receptor gamma in colonic epithelial cells protects against ex-Perimental Inflammatory bowel disease[J].Gut,2006,55:1104-1113.
[41]张燕,欧阳钦,陈代云PPAR-γ在溃疡性结肠炎粘膜中的表达[J].中华消化内镜杂志[J].2002,19：81-83.
[42]姚芳芳,郭长存,丁杰,等1RUNX3、SLC22A4和PPAR-γ的基因多态性与溃疡性结肠炎的关系[J].现代生物医学进展,2010,10(7)：1217-1220.
[43]李楠,王雪明,翟俊山,等.复方血竭对溃疡性结肠炎大鼠模型结肠组织细胞因子的调节作用[J],中国实验方剂学杂志,2008,14(1)：53-54.
[44]卢健,马骥,王丽娜,等.四逆散对实验性溃疡性结肠炎大鼠IL-1β的影响[J].中国实验方剂学杂志,2011,17(1)：103-105.
[45]Tjandra KLe T, Swain M G. Experimental colitisattenuates development of toxin-induced cholangitis in rats[J]. Dig Dis Sci,2002,47:1216.
[46]邓辉,钦丹萍.中医药对溃疡性结肠炎细胞因子的干预研究[J].中国中西医结合消化杂志,2006,14(5)344-346.
[47]Li Z, Zhang DK, Yi WQ, et al. NF-kappaB p65 antisense oligonu-cleotides may serve as a novel molecular approach for the treatmentof patients with ulcerative colitis [J]. Arch Med Res,2008,39(8):729-734.
[48]何雁,王志红,杨善峰,等.TLR9和NF-κBp65在大鼠溃疡性结肠炎模型结肠组织中的表达[J].安徽医药,2012,16(7)：938-940.
[49]杜立阳,陈铭诗,刘清芳,等.复方青黛颗粒对溃疡性结肠炎大鼠NF-κB P65、TNF-α表达的影响[J].世界华人消化杂志,2011,19(12)：1290-1294.
[50]荣英蕊,刘建平,陈建权,等.泄浊解毒方对溃疡性结肠炎大鼠结肠组织NF-κBp65及ICAM-1表达的影响,上海中医药杂志[J].2010 44(3)：63-65.
[2]桑力轩,刘汉立,姜敏.溃疡性结肠炎发病机制研究进展[J].世界华人消化杂志2007,15(20)：2249-2254.
[3]周婷婷,仝巧云.溃疡性结肠炎发病机制的研究进展[J].胃肠病学和肝病学杂志,2012,21(12)：1163-1166.
[4]纪桂贤,郑岳.溃疡性结肠炎治疗进展[J].中国误诊学杂志,2011,11(13)：3048-3051.
[5]樊慧丽,陈玉梅.溃疡性结肠炎的发病机制和治疗进展[J].中国全科医学,2012,15(1)：228-231.
[6]溃疡性结肠炎中医诊疗共识意见[J].中华中医药杂志(原中国医药学报),2010,25(6)：891-894.
[6]苗新普, 欧阳钦,韦红,黄咏东.溃疡性结肠炎组织中5-LOX、PPARγ和NF-κBP65的表达及意义[J].实用医学杂志,2011,27(10)：1757-1760.
[7]Atreya I, Atreya R, Neurath M F. NF-kappaB in inflammatorybowel disease [J]. J Intern Med,2008,263 (6):591-596.
[8]Jupp J, Hillier K, Elliott D H, et al. Colonic expression ofleukotriene-pathway enzymes in inflammatory bowel diseases[J]. Inflamm Bowel Dis,2007,13 (5):537-546.
[9]Katz JA, Itoh J, Fiocchi C. Pathogenesis of inflam-matory bowel disease. Curr Opin Gastroenterol 1999;15:291-297.
[10]Neurath MF, Meyer zum Buschenfelde KH. Protec-tive and pathogenic roles of cytokines in inflamma-tory bowel diseases[J]. J Investig Med 1996; 44:516-521.
[11]李春雷,陈治水.白介素在溃疡性结肠炎发病机制中的研究进展[J].现代消化及介入诊疗,2008,13(2)：146-149.
[12]张文俊,许国铭,李兆中,等.血清白细胞介素1p与溃疡性结肠炎的关系[J].第二军医大学学报.2002,23(6)：1345-1347.
[13]庞艳华,郑长青Th1/Th2细胞亚群与炎症性肠病的关系[J].世界华人消化杂志,2004,12(5)：1922-1924.
[14]口锁堂,吴焕淦,施达仁.白介素与溃疡性结肠炎[J].世界华人消化杂志,2006,14(3)405-411.
[15]王新月,杨莉莉,王雪茜,等.溃结饮不同给药途径对溃疡性结肠炎大鼠前炎性细胞因子表达的影响[J].中国中西医结合消化杂志.2006,14(3)：351-354.
[16]Tian L, Huang YX, Tian M,et al. Downregulation of elec-troacupuncture at ST36 on TNF-alpha in rats with ulcerativecolitis[J]. World J Gastroenterol,2003,9(5):1028-1033.
[17]陈垦,梁坚,周宇,等.溃疡性结肠炎病人血清SIL IR和TNF-α水平的变化及意义探讨[J].中国肛肠病杂志,1999,19(7)：9-11.
[18]李琪佳,徐敏,宫恩聪,等.细胞因子与溃疡性结肠炎[J].中国煤炭工业医学杂志,2001,4(6)：411-412.
[19]秦越人,《难经》[M].人民卫生出版社,1979.
[20]郭霭春,《黄帝内经素问语译》[M].人民卫生出版社,1995.
[21]龚廷贤,《寿世保元》,《龚廷贤医学全书》[M],中国中医药出版社,1999,564.
[22]张仲景,(宋本新辑)重庆市中医学会编注,《伤寒论》[M].重庆人民出版社,1955,97,108.
[23]巢元方,《诸病源候论》[M].人民卫生出版社影印本,1955.
[24]孙一奎,《赤水玄珠》,《孙一奎医学全书》[M].中国中医药出版社,1999,193,202.
[25]张景岳,《景岳全书》[M].人民卫生出版社,1991.
[26]陈言,《三因极一病证方论》[M].人民卫生出版社,1957.
[27]严用和,《济生方》,《古今图书集成医部全录》[M].人民卫生出版社,1962,864.
[28]陈十铎,《辨证录》[M].人民卫生出版社,1989,429,438-439.
[29]林佩琴,《类证治裁》[M].中医综合类名著集成.华夏出版社,1997.
[30]吴佳,李胜吾,张镭潇,等.从《黄帝内经》辨析溃疡性结肠炎的病因病机及预后[J].山东中医杂志2012,31(5)：309-310
[31]朱立,王新月.溃疡性结肠炎病因病机理论探讨[J].吉林中医药2010,30(1)：10-11.
[32]肖培新.溃疡性结肠炎病因病机认识及诊治体会[J].中国民间疗法,201],19(7)：5-6.
[33]赵景明.溃疡性结肠炎病因病机认识进展[J].中医学报,2010,23(5)：23-25.
[34]姜桂宁.溃疡性结肠炎病因病机探讨[J].山东中医杂志2008,27(4)：219-223
[35]吴家玮.溃疡性结肠炎病因病机特点与中医辨治思路[J].内蒙古中医药,2011,53(6)：7-9.
[36]王新月,田德禄.溃疡性结肠炎病因病理特点与中医辨治思路对策[J].北京中医药大学学报,2007,30(8)：554-559
[37]李梅,张苏闽.溃疡性结肠炎病因分析及预防[J].中医学报,2012,27(173)：1343-1345.
[38]姜杰新.溃疡性结肠炎病因及发病机制的研究进展[J].医师进修杂志,2004,27(12)：51-520.
[39]韩捷.溃疡性结肠炎病因及中医研究进展[J].中医药信息,2002,19(5)：4-6
[40]王丽.溃疡性结肠炎病因及中医证治浅析[J].中医药学刊,2004,22(12)：2778-2779
[41]唐容川,《血证论》[M].上海人民出版社,1977.
[42]张昶,《百病问对辨疑》,《中医临床经典》[M].上海中医药大学出版社,1997,483-486.
[43]王纶,《明医杂著》,《古今图书集成医部全录》[M].人民卫生出版社,1962,881,883.
[44]赵估,《圣济总录》[M].人民卫生出版社,1962.
[45]汪机,《医学原理》,《汪石山医学全书》[M].中国中医药出版社,1999,695-696.
[46]戴宝林.溃疡性结肠炎病因病机探讨及辨治体会[J].天津中医学院学报,2001,20(3)：37-38
[47]林燕,李建.基于“毒损肠络”理论的溃疡性结肠炎复发病机探微[J].中国临床医生,2012,40(11)：9-11.
[48]焦君良,要丽瑛,李士军,等.从痈论治溃疡性结肠炎初探[J].中国中西医结合脾胃杂志,2000,8(2)：100-103.
[49]曹婷婷.溃疡性结肠炎不同病情分期病机证治探析[J].江西中医药,2012,43(355)：7.
[50]段永强,梁玉杰,成映霞,等.论“肝郁脾虚”病机在溃疡性结肠炎中的病理意义及其相关性[J].辽宁中医药大学学报,2007,9(5)3-4.
[51]韩捷.脾虚湿热型溃疡性结肠炎的临床特点[J].中国实验方剂学杂志,2010,16(10)：191-192.
[52]刘敏,崔红生.溃疡性结肠炎的病机演变规律及用药体会[J].河北中医学院学报,1995,10(3)：16-17.
[53]贺海辉,沈洪,叶柏.溃疡性结肠炎活动期的病机与治法[J].南京中医药大学学报,2012,28(6)504-512.
[54]王希利,彭艳红,孙明祎,等.溃疡性结肠炎痰瘀病机要素探析[J].中华中医药学刊,2007,25(4)：720-721.
[55]陈江.溃疡性结肠炎中医病机演变及证治探讨[J].新中医,2005,37(4)：11-12
[56]范恒,邱明义,段雪理,等.肠四方治疗溃疡性结肠炎病机探讨[J].贵阳中医学院学报,2004,26(4)：17-19.
[57]李恒谋.脾虚型慢性结肠炎、溃疡性结肠炎的病机特点及治疗规律[J].华人消化杂志,1998,6(8)：726-728.
[58]中华中医药学会编著.中医内科常见病诊疗指南·西医疾病部分[M].中国中医药出版社,2008：107-110.
[59]马登斌,晓敏.溃疡性结肠炎中医药治疗的点滴体会[J].医学信息,2010,20(3)：409-410.
[60]倪海.辨证论治溃疡性结肠炎58例[C].甘肃省中医药学会2010年会员代表大会 暨学术年会论文汇编,2011.
[61]范素琴,李玉琢.辨证治疗溃疡性结肠炎46例[J].中医临床研究,2011,3(13)：83-84.
[62]曹景龙.溃疡性结肠炎中医辨证治疗36例分析[J].中外医疗,2010,31(2)：134.
[63]赵克华.辨证分型治疗溃疡性结肠炎[J].中医学报,2010,2(25)：329-330.
[64]张广业,邢继霞,党传玲.辨证论治配合灌肠治疗溃疡性结肠炎67例[J].新中医,2005,37(2)：69-70.
[65]黄文武.中医辨证论治治疗慢性溃疡性结肠炎56例[J].井冈山学院学报,2006,27(2)：122-123.
[66]安雪峰,赵继国,任茜.中医辨证分型治疗慢性结肠炎82例[J].四川中医,2005,23(9)：63-64.
[67]陈剑明,张声生,崔超.基于经验辨证的溃疡性结肠炎常见证候及证候要素的临床研究[J].北京中医药2011,30(6)：418-420.
[68]张会珍,刘建平.许占民教授治疗慢性非特异性溃疡性结肠炎临床经验撷要[J].新中医,2002,34(11)：14-16.
[69]张洪俊.加味痛泻要方治疗慢性结肠炎32例[J].陕西中医,1995,16(7)： 302.
[70]程卫军.疏肝健脾法治疗溃疡性结肠炎的临床观察[J].中国中西医结合杂志,2001,2](1)：34.
[71]田德禄,田海河.慢性非特异性溃疡性结肠炎中医研究述评[J].北京中医药大学学报,1994,17(6)：2-6.
[72陈业强,凌江红.从脑肠肽进行肝郁证与功能性消化不良病证结合研究的思路[J].中医杂志,2006,47(10)：784.
[73]衣蕾,聂丹丽.脾虚证的现代医学研究进展[J].陕西中医学院学报,2005,28(3)：59.
[74]曹小玉,杨智梅,彭成. 四君子颗粒抗脾虚动物胃肠细胞损伤的研究[J].成都中医药大学学报,2000,23(3)：32.
[75]毛海燕. 肝郁证大鼠肝线粒体膜流动性、血浆胃动素及血清胃泌素的变化及意义[J]. 福建中医药,2003,34(3)：42.
[76]肖桂林. 肝郁脾虚证实验诊断指标的研究[J]. 湖南中医学院学报,1998,18(2)：4.
[77]骆天炯.健脾疏肝法对肠易激综合征血浆及粘膜B内啡肽的调节作用[J].中国中西医结合杂志,2003,23(8)：616.
[78]黄穗平.从肝论治肠易激综合征[J]. 中医杂志,1990,31(3)：31.
[79]周玫.非特异性溃疡性结肠炎中西医结合诊治研究进展[J].中西医结合杂志,1988, 8(3)：184.
[80]许晓丽,王凤仪.溃疡性结肠炎中医证素分布及组合规律的文献分析[J].亚太传统医药,2011,7(5)：131-132.
[81]张北平,刘思德,李明松,等.溃疡性结肠炎内镜分型、黏膜织学分期与中医虚实证候的相关性研究[J].中国消化内镜,2008,2(3)：5-8.
[82]周秀丽,邢军,常丽丽.溃疡性结肠炎外周血黏附分子表达增高及其在中西医结合辨证分型相关性研究中的意义[J].河北医药,2008,30(7)：958-959.
[83]徐璠.培土抑木法在防治结肠炎中的应用[J].陕西中医,2006,27(12)：1548-1549.
[84]刘建波. 痛泻要方加减治疗肝郁脾虚型慢性溃疡性结肠炎28例[J].安徽中医临床杂志,2002,14(4)：175-176.
[85]韩建庆,范宇.健脾疏肝活血法治疗慢性溃疡性结肠炎47例[J].中医临床研究,2010,2(5)：42-43.
[86]邹信字.疏肝健脾法治疗慢性结肠炎32例[J].湖南中医药导报,2003,9(4)：27-28.
[87]程卫军.疏肝健脾法治疗溃疡性结肠炎的临床观察[J].中国中西医结合杂志,2001,21(1)：34-36.
[88]刘红芬,常丽丽,周晓娜,等.不同中医证型溃疡性结肠炎患者血清干扰素-γ和白细胞介素-4水平的变化[J].中国医药导刊,2008,10(6)：900-901.
[89]常丽丽,张淑梅,李光难,等.不同中医证型溃疡性结肠炎患者免疫球蛋白水平的研究[J]. 中国医药导刊,2008,10(8)：1221-1224.
[90]陈俊玲,曾斌.不同中医证型维吾尔族溃疡性结肠炎患者免疫球蛋白水平的研究[J]. 现代中西医结合杂志,2009,18(31)：3815-3816.
[91]王丽娜,范颖,卢健,林庶茹.四逆散干预实验性溃疡性结肠炎的药效学研究[J].中医研究,2011,24(2)：11-13.
[92]刘学芳,丁国萍. 疏肝健脾法治疗慢性结肠炎28例[J].社区医学杂志,2007,5(22)：27-28.
[93]王正君,张海燕. 结肠汤治疗溃疡性结肠炎62例[J].陕西中医,2005,26(1)：37-38.
[94]李雅萍.运用调和肝脾法治疗慢性结肠炎[J]. 包头医学,2007,31(4)：226.
[95]王玉杰,谢鸣.疏肝方、健脾方、疏肝健脾方对肝郁脾虚证模型大鼠IL-2、IL-6及T淋巴细胞增殖率的影响[J].北京中医药大学学报,2009,32(6)：398-401.
[96]叶仕.疏肝健脾法对肝郁脾虚型溃疡性结肠炎患者肠黏膜ICAM-1、VCAM-1表达的影响[C]／/2006年广东省中医、中西医结合脾胃消化病学术会议论文汇编.广州：2006年广东省中医、中西医结合脾胃消化病学术会议,2006： 274-279.
[97]陈俊玲,曾斌.不同中医证型维吾尔族溃疡性结肠炎患者免疫球蛋白水平的研究[J].现代中西医结合杂志,2009,18(31)：3815-3816.
[98]郭军雄.中医对溃疡性结肠炎的认识[J].中医研究,2010,23(10)：9-10.
[99]李云.溃疡性结肠炎治疗心法[J].中医研究,2009,22(7)：57-59.
[100]李云海,张雪荣.陈国权教授治疗溃疡性结肠炎经验[J].中医研究,2006,19(7)：4-48.
[101]顾立刚,郭学志.疏肝健脾方对溃疡性结肠炎肝郁脾虚证大鼠结肠溃疡的影响[J].北京中医药大学学报,2000,23(4)：24-26.
[102]秦震声,张燕生.疏肝健脾法对溃疡性结肠炎肝郁脾虚模型大鼠的治疗作用研究[J].中医研究,2007,20(5)：13-15.
[103]赖象权,何本求,周宏燕,等.侗药五味止泻汤对溃疡性结肠炎大鼠血清IL-1, IL-10的影响[J].中国实验方剂学杂志,2012,18(17)：227-230.
[104]梁兴伦,吴闯,姜在龙.溃结2号方对溃疡性结肠炎大鼠溃疡组织中IL-1β及IL-10mRNA表达的影响[J].广州中医药大学学报,2012,29(4)：397-400.
[105]陶弘武,柳越冬.溃结安康汤对溃疡性结肠炎大鼠结肠组织IL-1p的作用及蛋白表达的影响[J].辽宁中医杂志,2009,36(6)：1025-1027.
[106]陈淑娜,刘若丹.罗格列酮联合美沙拉嗪治疗溃疡性结肠炎对IL-1β、TNF-a的影响[J].广西医学,2011,3(4)：432-435.
[107]荣英蕊,刘建平,郎晓猛.泄浊解毒方对溃疡性结肠炎大鼠TLR2及IL-8、IL-1β影响的研究[J].四川中医,2012,30(5)：33-35.
[108]谢力,邢之华.三皮汤对小鼠溃疡性结肠炎模型IL-2和IL-10表达的影响[J].中国实验方剂学杂志,2009,15(9)：67-69.
[109]邹阳王,兴友杨,孝芳.溃疡性结肠炎大鼠IL-2、CD44、CD54的实验研究[J].江西医学检验,2002,20(5)：281-283.
[110]古学文.溃疡性结肠炎患者血清IL-2及sIL-2R浓度变化的研究[J].临东和实脸医学杂志,2003,2(3)：153-155.
[111]郭建生,湛扩,彭宇.肠炎愈片对大鼠溃疡性结肠炎血清白介素-2、一氧化氮的影响研究[J].湖南中医药大学学报,2007,27(6)：18-21.
[112]李桂贤,黄勇华,唐梅.加味柴芍六君颗粒对实验性溃疡性结肠炎大鼠T淋巴细胞亚群及白介素-2的影响[J],广西中医药,2007,30(4)：51-53.
[113]林巧嫦,廖博贤,黄飞娜.白细胞介素IL-4、IL-17在溃疡性结肠炎中的表达[J].中国医药科学,2012,2(16)：44-45.
[114]王小军,调解汤对大鼠溃疡性结肠炎肝郁模型血清中1L-4水平的影响[J].辽宁中医药大学学报,2009,11(3)：194-195.
[115]郝丽君,唐文君,郑荣娟.谷胺酰胺颗粒灌肠对溃疡性结肠炎患者IFN-γ、IL-4IL-8的影响及疗效观察[J].中华医院感染学杂志,2011,21(22)：4742-4744.
[116]黄芪多糖对溃疡性结肠炎大鼠血清IL-4、IL-5和IL-13水平的影响[J].贵阳中医学院学报,贵阳中医学院学报,2011,33(4)：23-25.
[117]王晓梅,郑世江,李静.溃结结合剂对溃疡性结肠炎大鼠IL-1β和IL-4的影响[J].山西中医学院学报,2006,7(5)：18-19.
[118]王雪茜,王新月.溃结饮2种给药途径对大鼠溃疡性结肠炎血清IFN-y和IL-4的影响[J].北京中医药大学学报,2010,33(7)：468-470.
[1]9]岳文杰,刘懿,徐薇,溃疡性结肠炎(UC)肠黏膜中IL-2、IL-4、IL-17和IL-10 的表达特点及其与疾病活动度的关系[J].复旦学报(医学版),2012,39(5)：454-457.
[120]卢健,于彩娜,马骥.四逆散对实验性溃疡性结肠炎大鼠IL-4的影响[J].中华中医药学刊,2011,29(4)：813-814.
[121]戴思思,董克礼.愈疡灌肠方治疗溃疡性结肠炎疗效及对血清IL-4 IL-10的影响[J].辽宁中医药大学学报,2010,12(2)：152-153.
[122]吴先哲,熊益群,邢国良.黄芪多糖对溃疡性结肠炎大鼠血清IL-4、IL-5和IL-13水平的影响[J].贵阳中医学院学报,2011,33(4)：23-25.
[123]宋爱玲TNF-a、IL-6、IL-8与溃疡性结肠炎严重程度相关研究[J].中国实用医药,2008,3(36)：3-5.
[124]厉洁,曲海霞,卫红军.溃疡性结肠炎患者炎症黏膜中IL-6、IL-23的表达及其临床意义[J].胃肠病学,2011,16(3)：164-165.
[125]马普伟,陈金泉,林锡芬.中医清热化湿法对溃疡性结肠炎患者血清TNF-a和IL-6的影响[J].江西中医学院学报,2010,22(1)：62-63.
[126]陈强妹,美沙拉嗪缓释颗粒对溃疡性结肠炎患者血清IL-6、TNF-α影响机制的研究[J].2011,49(36)：34-35.
[127]刘青梅,韩辅,陈曦.肠康饮对溃疡性结肠炎大鼠血清IL-6、IL-10的影响[J].世界中西医结合杂志2008,3(5)：266-268.
[128]潘勇,舒洪权,颜景颖.结肠康Ⅰ号对溃疡性结肠炎大鼠血清IL-6、IL-10的影响[J].中国民族民间医药,2011,3(20)：86-89.
[129]王觅柱,邬彩虹,陈吉.溃疡性结肠炎患者血清IL-1β、TNF-α和IL-10的表达及其意义[J].国际消化病杂志2009,29(5)：362-366.
[130]孙建华,吴闯,姜在龙.溃结2号方对溃疡性结肠炎大鼠溃疡组织中TNF-α及其mRNA表达的影响[J].上海中医药杂志,2012,46(4)：65-68.
[131]金纯,李霞,金可可.葛仙汤对溃疡性结肠炎大鼠结肠TNF-α和iNOS表达的干预作用[J].医学研究杂志2012,41(9)：115-118.
132]谭彬,赵己未.溃疡性结肠炎患者血清IL-13、IL-8的水平变化及意义[J].临床医学工程,2012,19(4)：581-582.
[133]刘力,张欢,马文军.马齿苋水煎剂对溃疡性结肠炎小鼠结肠组织中IL-8、IL-10表达的影响[J].辽宁中医药大学学报,2011,13(5)：18-20.
[134]姚民武,李保良,黄水清.乌梅丸对溃疡性结肠炎患者血清TNF-a、IL-6及IL-8含量的影响[J].医学信息,2010,8：2188-2189.
[135]周红光,陈海彬,徐肇敏.溃克灵对溃疡性结肠炎模型大鼠血清IL-8含量的影响[J].南京医科大学学报,2009,29(4)：488-490.
[136]李进,杨锐,邓豫IL-1β、IL-10在大鼠溃疡性结肠炎模型中的表达[J].,南昌大学学报,2010,50(12)：41-44.
[137]李贞娟,张彩凤,韩宇.IL-10单核营酸多态性与溃疡性结肠炎的相关性研究[J]. 山东医药,2012,52(13)：49-51.
[138]梁兴伦,吴闯,姜在龙.溃结2号方对溃疡性结肠炎大鼠溃疡组织中IL-1p及IL10 mRNA表达的影响[J].广州中医药大学学报,2012,29(4)：397-400.
[139]陶弘武,柳越冬.溃结安康汤对溃疡性结肠炎大鼠结肠组织IL-10的作用及蛋白表达的影响[J].中华中医药学刊,2009,27(6)：1257-1259.
[140]谢力,邢之华,蒋荣鑫.三皮汤对小鼠溃疡性结肠炎模型IL-2和IL-10表达的影响[J],中国实验方剂学杂志,2009,15(9)：67-69.
[141]张志杰,谢胜,马高峰.中医药对溃疡性结肠炎患者血清IL-8、IL-10的影响[J].陕西中医,2011,32(5)：566-568.
[142]贾长河,许泼实,康谊.溃疡性结肠炎患者血清IL-8、IL-10、TNF-a的水平及临床意义[J].中华实用诊断与治疗杂志,2008,22(8)：574-577.
[143]魏艳静,卞红磊.溃疡性结肠炎大鼠肠黏膜PPARy的表达[J].天津医药,2004,32(9)：568-569.
[144]Bassaganya-Riera J,Reynolds K,Martino-Catt S,et al.Activation of PPAR gamma and delta byconjugated linoleic acid mediates protection from experimental inflammatory bowel disease.Gastroenterology,2004,127(3):777-791
[145]Willson TM,Brown PJ,Sternbach DD,et al.The PPARs:from orphan receptors to drug discovery.Med Chem,2000,43(4):527-550.
[146]Bassaganya-Riera J,Reynolds K,Martino-Catt S,et al.Activation of PPAR gamma and delta byconjugated linoleic acid mediates protection from experimental inflammatory bowel disease.Gastroenterology,2004,127(3):777-791.
[147]柯希权,王启之,燕善军,等.溃疡性结肠炎大鼠结肠黏膜中MMP-3和PPAR-y的表达及其意义[J].胃肠病学和肝病学杂志,2009,18(9)：824-827.
[148]张燕,欧阳钦,陈代云PPAR-y在溃疡性结肠炎粘膜中的表达[J].中华消化内镜杂志,2002,19(2)：81-83.
[149]卞红磊,魏艳静,赵发.柳氮磺胺吡啶对溃疡性结肠炎大鼠结肠黏膜上皮PPARy表达的影响[J].广东医学,2004,25(1])：1258-1259.
[150]苗新普,欧阳钦,韦红COX-2. PPAR-y和NF-κB p65在溃疡性结肠炎组织中的表达及意义[J].世界华人消化杂志,2010,18(25)：2660-2665.
[151]梁红亮,欧阳钦.过氧化物酶体增生物激活受体-γ在小鼠嗯唑酮结肠炎中作用的研究[J].胃肠病学,2007,12(2)：101-105.
[152]周静平,邓长生.罗格列酮对大鼠溃疡性结肠炎的疗效及其机制[J].临床消化病杂志.2006,18(2)：84-85.
[153]Sen P,Wallet MA,et al.Apoptotic cells induce Mer Tyrosinekinase-DepEndent blockade ofNF-kappaB activation in dendritic cells.Blood,2007,109(2):65-660.
[154]陈维雄,陈金联,达炜,等.P选择素和ICAM-1对小鼠溃疡性结肠炎的研究[J].世界华人消化杂志,2002,10(6)：722-724.
[155]施征,张卫,吴焕,金艾灸对溃疡性结肠炎结肠粘膜IL-8、ICAM-1及其mRNA 表达的影响[J].中医药学刊,2004,22(6)：1011-1013.
[156]张运贵,张瑞玲,黄咏梅,等.二丙酸倍氯米松治疗溃疡性结肠炎的疗效及对P-选择素、ICAM-1表达影响研究[J].临床消化病杂志,2008,23(3)：176-178.
[157]杜群,李红,王汝俊.溃结灵对溃疡性结肠炎大鼠结肠粘膜[J].广州中医药大学学报,2008,25(3)：229-231.
[158]王小琴,孔超美,张予蜀.美沙拉嗪缓释颗粒(艾迪莎)对溃疡性结肠炎患者肠黏膜组织病理学改变及血清ICAM-1水平的影响[J].实用临床医药杂志,2010,14(17)：66-68.
[159]郑红斌,胡鸿毅,马贵同.清肠栓对溃疡性结肠炎实验大鼠ICAM-1表达的影响[J].浙江中医学院学报,2004,28(6)：44-46.
[160]李海龙,程小丽,董晓丽.NF-κB和ICAM-1在溃疡性结肠炎大鼠结肠中表达及中药干预的影响[J].中国老年学杂志,2011,9(31)：1594-1596.
[161]周红光,陈海彬,徐肇敏,于成功.溃克灵对溃疡性结肠炎大鼠模型结肠黏膜ICAM-1基因表达的影响[J].南京中医药大学学报,2009,25(3)：216-218.
[162]赵晓霞,郭胜,李宝鹤,虎勤.芍药汤对溃疡性结肠炎大鼠ICAM-1、TNF-α、IL-10影响的实验研究[J].中国中医药科技,2008,15(3)：174-176.
[163]王雪冰,安新茹.肠康灵汤对溃疡性结肠炎大鼠ICAM-1的影响[J].西部中医药,2011,24(7)22-24.
[164]张竹,方步武,朱爱江,等.痛泻要方的抗炎作用研究[J].中药药理与临床,25(4)：1-3.
[165]范恒,邱明义,梅家俊,等.理肠四方对溃疡性结肠炎大鼠组织细胞因子TNF-a、 IL-6、IL-8、IL-10的影响[J].中医药学刊,2004,22(9)：1624-1627
[166]胡旭光,利红宇.痛泻要方对肝郁脾虚型溃疡性结肠炎动物模型的治疗作用[J]..广东药学院学报,2004,20(1)：40-41.
[167]陈文莉,郭良集,莫宁,等.加味痛泻要方抗炎镇痛作用的实验研究[J].中国实验方剂学杂志,2007,13(5)：20-27.
[1]Sutherland L, MacDonald JK. Oral 5-aminosalicylicacid for induction of remission inulcerative colitis.Cochrane Database Syst Rev 2003; (3):CD000543
[2]Campieri M. New steroids and new salicylates ininflammatory bowel disease:a critical appraisal.Gut 2002; 50 Suppl 3:Ⅲ43-Ⅲ46
[3]Iacucci M, de Silva S, Ghosh S. Mesalazine in in-flammatory bowel disease:a trendy topiconceagain? Can J Gastroenterol 2010; 24:127-133
[4]Feagan BG, Macdonald JK. Oral 5-aminosalicylicacid for maintenance of remission in ulcerative coli-tis. Cochrane Database Syst Rev 2012; (10):CD000544
[5]Travis SP, Stange EF, Lemann M, Oresland T, Be-melman WA, Chowers Y, Colombel JF, D'HaensG, Ghosh S, Marteau P, Kruis W, Mortensen NJ,Penninckx F, Gassull M. European evidence-basedConsensus on the management of ulcerative colitis:Current management. J Crohns Colitis 2008; 2:24-62
[6]Marteau P, Probert CS, Lindgren S, Gassul M, TanTG, Dignass A, Befrits R, Midhagen G, RademakerJ, Foldager M. Combined oral and enema treatmentwith Pentasa (mesalazine) is superior to oral thera-py alone in patients with extensive mild/moderateactive ulcerative colitis:a randomised, double blind,placebo controlled study. Gut 2005; 54:960-965
[7]Kruis W, Kiudelis G, Racz I, Gorelov IA, Pokrot-nieks J, Horynski M, Batovsky M, Kykal J, BoehmS, Greinwald R, Mueiler R. Once daily versus threetimes daily mesalazine granules in active ulcer-ative colitis:a double-blind, double-dummy, ran-domised, non-inferiority trial. Gut 2009; 58:233-240
[8]Hussain FN, AjjanRA, KapurK, MoustafaM,Riley SA. Once versus divided dailydosing withdelayed-release mesalazine:a study of tissue drugconcentrations and standard pharmacokinetic pa-rameters. Aliment Pharmacol Ther 2001; 15:53-62
[9]Sandborn WJ, Korzenik J, Lashner B, Leighton JA,Mahadevan U, Marion JF, Safdi M, Sninsky CA,Patel RM, Friedenberg KA, Dunnmon P, Ramsey D,Kane S. Once-daily dosing of delayed-release oralmesalamine (400-mg tablet) is as effective as twice-daily dosing for maintenance of remission of ulcer-ative colitis. Gastroenterology 2010; 138: 1286-1296,1286-1296
[10]Dignass AU, Bokemeyer B, Adamek H, Mross M,Vinter-Jensen L, Borner N, Silvennoinen J, Tan G,Pool MO, Stijnen T, Dietel P, Klugmann T, VermeireS, Bhatt A, Veerman H. Mesalamine once daily ismore effective than twice daily in patients with qui-escent ulcerative colitis. Clin Gastroenterol Hepatol2009; 7:762-769
[11]Morris GP, Beck PL, Herridge MS, et al. Hapten-induced model of chronic inflammation and ulceration in the rat colon. Gastroenterology,1989,96(3):795-803
[12]郑礼,高振强,王淑仙.大鼠溃疡性结肠炎模型的实验研究[J].中国药理学通报,1998,14(4)：370-72
[13]郭振球,赵晓威.肝纤宁对肝郁脾虚大鼠的保肝抗纤作用[J].湖南中医学院学报,1998,18(2)：10-12
[14]韩秋艳.肝郁脾虚证动物模型的建立[J].贵阳中医学院学报,2001,23(3)：59-61
[13]顾立刚,郭学志,王庆国.大鼠溃疡性结肠炎肝郁脾虚证动物模型的研究[J].北京中医药大学学报,1999,22(2)：21-23
[15]湖南医学院第一附属医院中医基础理论研究室.肝郁脾虚的理论与实验研究[J].湖南医学院学报,1979,4(3)：131-143
[16]刘绍唐,陈道森,潘玲,等.穴位注射对实验性肝郁脾虚动物模型的影响[J].成都中医药大学学报,1995,18(3)：38-41.
[17]李艳彦,谢鸣,陈禹,等.肝郁脾虚证大鼠模型复制中的免疫系统变化[J].中华中医药杂志,2006,21(7)：428-429
[18]张芳艳,毛新民,武鸿莉,等.肝郁脾虚型溃疡性结肠炎大鼠的免疫学研究[J].新疆医科大学学报,2004,27(4)：367-369
[19]刘金玲,姚良权,聂路安.疏肝健脾治疗与肝郁脾虚因素刺激对大肠癌大鼠免疫功能变化的探讨[J].国际医药卫生导报,2006,12(3)：4-6
[20]唐已婷,陈家旭.束缚应激与中医肝的关系[J].中国医药学报,2002,17(2)：82-83
[21]李强.抗抑郁药及心理疗法在溃疡性结肠炎治疗中的作用[J].山东医药,2005,45(18)：56.
[22]石慧琳,应激对肠黏膜屏障功能的影响研究进展[J].国外医学消化病分册,2003,23(3)：164-167.
[23]邵枫.应激对免疫作用机制的研究进展[J].心理学动态,1999,7(3)：5.
[24]中华中医药学会脾胃病分会,溃疡性结肠炎中医诊疗共识意见[J],中华中医药杂志,2010,25(6)：891-895.
[25]路晓红,杨恩来,赵霞,等.溃疡性结肠炎免疫机制的研究进展[J].山西中医学院学报,2011,12(1)：66-68.
[26]李楠,王雪明,翟俊山,等.复方血竭对溃疡性结肠炎大鼠模型结肠组织细胞因子的调节作用[J],中国实验方剂学杂志,2008,14(1)：53-54.
[27]卢健,马骥,王丽娜,等.四逆散对实验性溃疡性结肠炎大鼠IL-1β的影响[J].中国实验方剂学杂志,2011,17(1)：103-105.
[28]Tjandra K, Le T, Swain M G. Experimental colitisattenuates development of toxin-induced cholangitis in rats[J]. Dig Dis Sci,2002,47:1216.
[29]邓辉,钦丹萍.中医药对溃疡性结肠炎细胞因子的干预研究[J].中国中西医结合消化杂志,2006,14(5)344-346.
[30]许欣,于成功.中医药治疗溃疡性结肠炎的实验研究[J].长春中医药大学学报,2012,28(1)：81-83.
[31]朱凌宇,顾贤,马贵同,等.三七提取物对三硝基苯磺酸诱导溃疡性结肠炎大鼠结肠血管生成的研究[J].中国中西医结合消化杂志,2008,16(2)：99-102.
[32]陈百齐,季成春,刘德龙,等.中医药治疗溃疡性结肠炎研究概况[J].实用中医内科杂 志,2012,26(3)：96-98.
[33]余欣,邱明义,胡继鹰,等.乌梅丸对溃疡性结肠炎大鼠肠组织核转录因子-κB及细胞间黏附分子1的影响[J].中国中西医结合消化杂志,2008,16(3)：172-174.
[34]赵晓霞,郭胜,李宝鹤.芍药汤对溃疡性结肠炎大鼠ICAM-1、TNF-α、IL-10影响的实验研究[J].中国中医药科技,2008,15(3)：174-176.
[35]周燕红,于皆平.银杏叶提取物对大鼠实验性结肠炎NF-κB和ICAM-1表达的影响[J],广东医学,2007,28(6)：889-891.
[36]柯希权,王启之,燕善军,等.溃疡性结肠炎大鼠结肠黏膜中MMP-3和PPAR-γ的表达及其意义[J]..胃肠病学和肝病学杂志,2009,18(9)：824-927.
[37]GillesS, MarianiV, BryceM, eta.l Pollen-derivedE1-phytoprostan-es signal via PPAR-ga mmaand NF-kappaB-dependent mechanisms[J]. J Immuno,l 2009,182(11):6653-6658.
[38]Duan SZ, UsherMG, Mortensen RM. PPARs:the vasculature, in-flammation and hypertension [J]. Curr Opin Nephrol Hypertens,2009,18(2):128-133.
[39]RousseauxC, Desreumaux P. The peroxisome-proliferator-activatedgamma receptor and chronic inflammatory bowel disease (PPARgam-ma and IBD) [J]. J Soc Bio,l 2006,200(2): 121-131.
[40]Adachi M,Kurotani R,Morimura K,et al.Peroxisome proliferator ac-tivated receptor gamma in colonic epithelial cells protects against ex-Perimental Inflammatory bowel disease[J].Gut,2006,55:1104-1113.
[41]张燕,欧阳钦,陈代云PPAR-γ在溃疡性结肠炎粘膜中的表达[J].中华消化内镜杂志[J].2002,19：81-83.
[42]姚芳芳,郭长存,丁杰,等1RUNX3、SLC22A4和PPAR-γ的基因多态性与溃疡性结肠炎的关系[J].现代生物医学进展,2010,10(7)：1217-1220.
[43]李楠,王雪明,翟俊山,等.复方血竭对溃疡性结肠炎大鼠模型结肠组织细胞因子的调节作用[J],中国实验方剂学杂志,2008,14(1)：53-54.
[44]卢健,马骥,王丽娜,等.四逆散对实验性溃疡性结肠炎大鼠IL-1β的影响[J].中国实验方剂学杂志,2011,17(1)：103-105.
[45]Tjandra KLe T, Swain M G. Experimental colitisattenuates development of toxin-induced cholangitis in rats[J]. Dig Dis Sci,2002,47:1216.
[46]邓辉,钦丹萍.中医药对溃疡性结肠炎细胞因子的干预研究[J].中国中西医结合消化杂志,2006,14(5)344-346.
[47]Li Z, Zhang DK, Yi WQ, et al. NF-kappaB p65 antisense oligonu-cleotides may serve as a novel molecular approach for the treatmentof patients with ulcerative colitis [J]. Arch Med Res,2008,39(8):729-734.
[48]何雁,王志红,杨善峰,等.TLR9和NF-κBp65在大鼠溃疡性结肠炎模型结肠组织中的表达[J].安徽医药,2012,16(7)：938-940.
[49]杜立阳,陈铭诗,刘清芳,等.复方青黛颗粒对溃疡性结肠炎大鼠NF-κB P65、TNF-α表达的影响[J].世界华人消化杂志,2011,19(12)：1290-1294.
[50]荣英蕊,刘建平,陈建权,等.泄浊解毒方对溃疡性结肠炎大鼠结肠组织NF-κBp65及ICAM-1表达的影响,上海中医药杂志[J].2010 44(3)：63-65.